Category Covid-19

PIER MARIA FORNASARI
2021-04-13

New Technique Provides Detailed Map of Lung Pathology in COVID-19. Disease progression may not depend on the persistence of the virus, but on an overreaction of the immune system.

A team led by investigators at Weill Cornell Medicine and NewYork-Presbyterian has used advanced technology and analytics to map, at single-cell resolution, the cellular landscape of diseased lung tissue in severe COVID-19 and other infectious lung diseases. In the study, published online March 29 in Nature, the researchers imaged autopsied lung tissue in a way that

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-04-13

What is Cerebral Venous Sinus Thrombosis (CVST), the post adenovirus Covid-19 vaccine rare clotting complication: Vaccine Immune Thrombotic Thrombocytopenia represents a small percent of cases. Need to define other cases diagnosis and treatment.

Cerebral venous sinus thrombosis (CVST) occurs when a blood clot forms in the brain’s venous sinuses. This  prevents blood from draining out of the brain. As a result, blood cells may break and leak blood into the brain tissues, forming a hemorrhage. This chain of events is part of a stroke that can occur in adults

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-04-13

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) shows that previous infection with SARS-CoV-2 induces effective immunity to future infections in most individuals.

Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. In a paper published on The Lancet it was investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. A large, multicentre, prospective cohort study was done, with participants

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-04-13

Letter from the Expert Haematology Panel and endorsed by Thrombosis UK, to the Medicines and Healthcare products Regulatory Agency (MHRA)

We wish to raise our concern with the MHRA regarding wording included in recent changes in MHRA guidance on the use of the AstraZeneca COVID-19 vaccine. The MHRA Guidance issued 7th April 2021 (https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots ) Indicates: The MHRA is not recommending age restrictions in COVID-19 Vaccine AstraZeneca use. As a precaution, administration of COVID-19 Vaccine AstraZeneca

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-04-12

World Federation of Hemophilia and European Hemophilia Consortium release joint statement on AstraZeneca COVID-19 vaccine

EMA, ISTH, WHO and many countries recommend benefit of COVID-19 vaccination outweighs the risks. Risks of adverse events no higher in people with bleeding disorders The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), following investigation of isolated cases of unusual blood clotting with low blood platelets that have occurred in a small number

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-04-10

University of Cambridge: Communicating the potential benefits and harms of the Astra-Zeneca COVID-19 vaccine

All medical treatments have potential harms as well as potential benefits, and it’s important to be able to weigh these against each other. With vaccines, the benefits are particularly complex as they can involve benefits to others as well as to ourselves – and the harms can feel particularly acute because we take vaccines when

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-04-10

In two papers on NEJM researchers find VITT as responsible of AstraZeneca’s vaccine causing clots in 16 of 222 thrombosis EMA reported cases over 30 milion doses. Even US four J&J vaccine thrombosis cases under EMA evaluation scrutiny.

Doctors might have figured out why AstraZeneca Vaccine Induced Immune Thrombotic Thrombocytopenia (VITT) may cause life-threatening blood clots in a group of 16 patients with very rare cases of thrombosis and thrombocytopenia. The discovery, made in a pair of reports published online Friday in the New England Journal of Medicine, could be key to the global

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-04-10

Helping the Public Understand Adverse Events Associated With COVID-19 Vaccinations

Lessons Learned From Functional Neurological Disorder Videos of people experiencing severe neurological symptoms, including convulsions and difficulty walking, purportedly after receiving a COVID-19 vaccine, have surfaced on Facebook, YouTube and other social media channels. The millions of people watching these videos might conclude that the vaccine is either quite dangerous to produce such symptoms or

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-04-09

Johnson & Johnson’s COVID-19 vaccine under EMA PRAC evaluation after 4 ‘serious cases’ of unusual blood clots

AstraZeneca’s COVID-19 vaccine has dominated headlines as reports of rare blood clots mounted, but, now, European drug safety regulators are investigating potential clotting risks from Johnson & Johnson’s vaccine. So far in the J&J vaccine’s U.S. rollout, EU officials have tracked three cases of unusual blood clots with low blood platelets following vaccination, the European

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-04-09

AstraZeneca COVID vaccine 70% effective vs B117 variant

Data from a UK phase 2/3 clinical trial suggest the AstraZeneca-Oxford COVID-vaccine is 70.4% effective against symptomatic COVID-19 caused by the B117 variant, which was identified in the United Kingdom in late 2020. The data, published in The Lancet yesterday, also showed it was 28.9% effective at preventing asymptomatic infections or cases with unknown symptoms. Overall efficacy was

Read More

No Comments InCovid-19